about
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancerOvarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility.The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple OrgansCDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland.A high proportion of founder BRCA1 mutations in Polish breast cancer families.CHEK2 is a multiorgan cancer susceptibility gene.Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.Common variants of DNA repair genes and malignant melanoma.Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationLow penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association ConsortiumA common variant of CDKN2A (p16) predisposes to breast cancer.Novel germline mutations in the adenomatous polyposis coli gene in Polish families with familial adenomatous polyposis.Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of DietPathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Prognostic factors in Polish patients with BRCA1-dependent ovarian cancerRAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern PolandAn inherited NBN mutation is associated with poor prognosis prostate cancerSystemic treatment for hereditary cancers: a 2012 update.Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort StudyResults of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.Are two-centimeter breast cancers large or small?Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.Clinical genetic services for familial breast cancer in Poland.
P50
Q24540270-F2E7710B-7888-4342-9212-191E82974144Q33327308-1179657E-F70A-46CE-84D4-4EE9D296F6CFQ33654709-F0F52347-3C22-4925-9D65-9BF099594A94Q33722537-BA08AFB3-F480-4F93-9FCC-E60BA762F3F4Q34306552-814CA5F9-7BCE-40DA-A635-3DC3A53EC634Q34548008-258AC0AB-EDEB-468D-9DE8-D7BF8F675118Q34551970-7DBAD5B3-27E0-46F0-A991-752F902F1C75Q34572576-DF9C11CF-AA38-453B-BFCC-20319F499756Q34579373-B25DE6A6-6121-4059-9338-788EAB1E156EQ34585088-66796C50-A261-4CEB-B884-0DDF5C7C6F70Q34949394-3635DE5C-43D4-49B5-8CF8-E37998639E6DQ34988799-80517B5B-883E-47F4-8937-6BC68D6F7061Q35022825-00F7CF8A-2E52-471A-89A6-F3411B019904Q35022847-68FD0A32-8C1E-430E-989B-E53522C726C8Q35089479-12EE3F86-C1D8-44D9-BE0F-8ADED0CB83BCQ35119701-D78E6E3B-88C1-4803-A61F-7B7C8DBB752FQ35447197-588543B5-84A1-45E5-BC59-A6DF5B97915EQ35559901-A4B8234F-6BC3-4FF5-AA13-D4C38F25E79DQ35870067-8E4BCFE7-A035-4B72-9F89-A6C266BB0125Q35907001-0BB126DF-8996-4361-8862-020D5FF83645Q35957703-7404ADEA-4ACA-419F-98ED-C24D15938942Q36072765-C0CE51F4-F303-43A5-A2B1-05C474741F26Q36108172-E0ACBBE8-5B10-4BCF-99B1-BEA58C2A8A9CQ36132338-760C7238-08F5-432A-AA27-D7D27FF82875Q36152991-06DC1549-938E-4BDE-A29C-F365A1202F35Q36280191-9837DA9C-B2F3-4484-8C8A-BA1B4C53DF5CQ36494555-593B69CC-2101-4BEB-A7AA-ED7C515435F3Q36512097-ED013B8D-88B6-4E24-A832-3C9987A918D3Q36538025-70DACAA3-7679-4B33-B886-95D3FCA22B7BQ36594121-54FAE88B-74EE-4BA7-9AD2-A38D204E1FA3Q36755366-F9D281B1-9D0A-46E5-B6AA-CDE6EF588EC8Q36839777-62BCF201-20C8-441F-A3B8-55DFBE122252Q36897003-8268B6A0-7B43-457F-BF91-B11F42DA1BA4Q36898423-2625E3AA-431E-49DA-B70F-28D8CB813FF1Q36924418-1160A51A-5526-4A7F-9E12-36E2F241B0C4Q36927109-88555254-0626-4C01-B913-0F09CF65C59FQ37056869-53A21CCA-F4BF-469B-BAFE-948EC92B41F8Q37222641-D7308AE9-B704-4D83-AD48-2849D0A5B7B4Q37249356-BF3D7512-D3D3-4833-A76E-5607370136CEQ37363736-1C6F323F-BFA5-4A3A-9825-C36E4E8AEAF7
P50
description
Polish oncologist
@en
Pools onderzoeker
@nl
oncólogo polaco
@es
polski lekarz onkolog
@pl
name
Tomasz Byrski
@ast
Tomasz Byrski
@ca
Tomasz Byrski
@de
Tomasz Byrski
@en
Tomasz Byrski
@es
Tomasz Byrski
@fr
Tomasz Byrski
@ga
Tomasz Byrski
@gl
Tomasz Byrski
@it
Tomasz Byrski
@nl
type
label
Tomasz Byrski
@ast
Tomasz Byrski
@ca
Tomasz Byrski
@de
Tomasz Byrski
@en
Tomasz Byrski
@es
Tomasz Byrski
@fr
Tomasz Byrski
@ga
Tomasz Byrski
@gl
Tomasz Byrski
@it
Tomasz Byrski
@nl
prefLabel
Tomasz Byrski
@ast
Tomasz Byrski
@ca
Tomasz Byrski
@de
Tomasz Byrski
@en
Tomasz Byrski
@es
Tomasz Byrski
@fr
Tomasz Byrski
@ga
Tomasz Byrski
@gl
Tomasz Byrski
@it
Tomasz Byrski
@nl
P214
P101
P1053
I-2844-2014
P106
P1412
P1559
Tomasz Byrski
@pl
P21
P214
P27
P31
P3829
P496
0000-0001-9181-5026
P735
P7859
viaf-162363407